In contrast, the PAX7 target gene repression biomarker can be readily measured on all FSHD cells isolated by van den Heuvel et al. (2019) (32) and is a significantly better classifier than biomarkers based on DUX4 target gene expression with a better scalability as biopsy size drops. This evidence concerns the gene PAX7 and facioscapulohumeral muscular dystrophy.